Drimartol B, a sesquiterpene coumarin of the edible powder of Artemisia sphaerocephala seed, induced apoptosis in NSCLC cells via PI3K/AKT/FoxO3a pathway inhibition by Jiwen Li, Zhongyu Li, Mengru Cui, Mei Sun, Lei Men, Xiaojie Gong, Keke Li

Subjects: Get full text

Editorial: Insights in clinical and translational physiology: 2023 by Gaetano Santulli, Gaetano Santulli, Gaetano Santulli, Markus W. Hollmann, Christina M. Pabelick, Johannes J. Van Lieshout, Johannes J. Van Lieshout

Subjects: “…non-small-cell lung cancer (NLSCLC)…”
Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

Subjects: Get full text

IINS Vs CALLY Index: A Battle of Prognostic Value in NSCLC Patients Following Surgery by Cheng H, Ma J, Zhao F, Liu Y, Wu J, Wu T, Li H, Zhang B, Liu H, Fu J, He H, Zhu C, Ren H, Yang C, Qin S

Subjects: “…non-small cell lung cancer (nsclc)…”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

Subjects: Get full text

Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study by Shuta Ohara, MD, PhD, Kenichi Suda, MD, PhD, Sumedha Sudhaman, PhD, Akira Hamada, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Toshiki Takemoto, MD, PhD, Ekaterina Kalashnikova, PhD, Samantha K. Cheung, PhD, Michael Krainock, MD, PhD, Jordan Feeney, BS, Himanshu Sethi, MPH, Minetta C. Liu, MD, Junichi Soh, MD, PhD, Yasuhiro Tsutani, MD, PhD, Tetsuya Mitsudomi, MD, PhD

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

Subjects: “…non-small cell lung cancer (NSCLC)…”
Get full text

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizu... by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

Subjects:

Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H2O2 by C.F. Pulliam, M.A. Fath, S. Sho, S.T. Johnson, B.A. Wagner, M. Singhania, A.L. Kalen, K. Bayanbold, S.R. Solst, B.G. Allen, B.N. George, J.M. Caster, G.R. Buettner, D.P. Riley, J.L. Keene, R.A. Beardsley, D.R. Spitz

Subjects: Get full text